Research programme: mRNA therapeutics - Arcturus Therapeutics/Ultragenyx Pharmaceutical

Drug Profile

Research programme: mRNA therapeutics - Arcturus Therapeutics/Ultragenyx Pharmaceutical

Alternative Names: LUNAR-GSDIII

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arcturus Therapeutics
  • Developer Arcturus Therapeutics; Ultragenyx Pharmaceutical
  • Class RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 14 May 2018 Preclinical trials in Undefined indication in USA (Parenteral)
  • 16 Mar 2016 Arcturus Therapeutics receives intent to grant notice from the European Patent Office for their unlocked nucleomonomer agent (UNA) Technology
  • 29 Oct 2015 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top